Literature DB >> 22181002

Proteomic analysis of colorectal cancer metastasis: stathmin-1 revealed as a player in cancer cell migration and prognostic marker.

Hwee Tong Tan1, Wei Wu, Yi Zhen Ng, Xuxiao Zhang, Benedict Yan, Chee Wee Ong, Sandra Tan, Manuel Salto-Tellez, Shing Chuan Hooi, Maxey C M Chung.   

Abstract

Metastasis accounts largely for the high mortality rate of colorectal cancer (CRC) patients. In this study, we performed comparative proteome analysis of primary CRC cell lines HCT-116 and its metastatic derivative E1 using 2-D DIGE. We identified 74 differentially expressed proteins, many of which function in transcription, translation, angiogenesis signal transduction, or cytoskeletal remodeling pathways, which are indispensable cellular processes involved in the metastatic cascade. Among these proteins, stathmin-1 (STMN1) was found to be highly up-regulated in E1 as compared to HCT-116 and was thus selected for further functional studies. Our results showed that perturbations in STMN1 levels resulted in significant changes in cell migration, invasion, adhesion, and colony formation. We further showed that the differential expression of STMN1 correlated with the cells' metastatic potential in other paradigms of CRC models. Using immunohistochemistry, we also showed that STMN1 was highly expressed in colorectal primary tumors and metastatic tissues as compared to the adjacent normal colorectal tissues. Furthermore, we also showed via tissue microarray analyses of 324 CRC tissues and Kaplan-Meier survival plot that CRC patients with higher expression of STMN1 have poorer prognosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22181002     DOI: 10.1021/pr2010956

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  22 in total

1.  Stathmin in pancreatic neuroendocrine neoplasms: a marker of proliferation and PI3K signaling.

Authors:  Simon Schimmack; Andrew Taylor; Ben Lawrence; Hubertus Schmitz-Winnenthal; Lars Fischer; Markus W Büchler; Irvin M Modlin; Mark Kidd; Laura H Tang
Journal:  Tumour Biol       Date:  2014-09-30

2.  High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study.

Authors:  Henry D Reyes; Jeffrey Miecznikowski; Jesus Gonzalez-Bosquet; Eric J Devor; Yuping Zhang; Kristina W Thiel; Megan I Samuelson; Megan McDonald; Jean-Marie Stephan; Parviz Hanjani; Saketh Guntupalli; Krishnansu S Tewari; Floor Backes; Nilsa Ramirez; Gini F Fleming; Virginia Filiaci; Michael J Birrer; Kimberly K Leslie
Journal:  Gynecol Oncol       Date:  2017-05-19       Impact factor: 5.482

3.  miR-193b directly targets STMN1 and inhibits the malignant phenotype in colorectal cancer.

Authors:  Feng Guo; Yang Luo; Yi-Fei Mu; Shao-Lan Qin; Yang Qi; Yi-Er Qiu; Ming Zhong
Journal:  Am J Cancer Res       Date:  2016-11-01       Impact factor: 6.166

4.  Elevated STMN1 Expression Correlates with Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma.

Authors:  Jian Li; Guohuang Hu; Fujiao Kong; Kemin Wu; Kun Song; Jianfeng He; Weijia Sun
Journal:  Pathol Oncol Res       Date:  2015-03-20       Impact factor: 3.201

5.  A combination of paclitaxel and siRNA-mediated silencing of Stathmin inhibits growth and promotes apoptosis of nasopharyngeal carcinoma cells.

Authors:  Yong Wu; Min Tang; Yuan Wu; Xinxian Weng; Lifang Yang; Wen Xu; Wie Yi; Jinghe Gao; Ann M Bode; Zigang Dong; Ya Cao
Journal:  Cell Oncol (Dordr)       Date:  2013-12-05       Impact factor: 6.730

6.  Zyxin (ZYX) promotes invasion and acts as a biomarker for aggressive phenotypes of human glioblastoma multiforme.

Authors:  Xian-Mei Wen; Tao Luo; Yi Jiang; Li-Hong Wang; Ying Luo; Qian Chen; Kaidi Yang; Ye Yuan; Chunhua Luo; Xiang Zhang; Ze-Xuan Yan; Wen-Juan Fu; Yu-Huan Tan; Qin Niu; Jing-Fang Xiao; Lu Chen; Jiao Wang; Jia-Feng Huang; You-Hong Cui; Xia Zhang; Yan Wang; Xiu-Wu Bian
Journal:  Lab Invest       Date:  2020-01-16       Impact factor: 5.662

7.  RSK2 signals through stathmin to promote microtubule dynamics and tumor metastasis.

Authors:  G N Alesi; L Jin; D Li; K R Magliocca; Y Kang; Z G Chen; D M Shin; F R Khuri; S Kang
Journal:  Oncogene       Date:  2016-04-04       Impact factor: 9.867

8.  Stathmin is dispensable for tumor onset in mice.

Authors:  Sara D'Andrea; Stefania Berton; Ilenia Segatto; Linda Fabris; Vincenzo Canzonieri; Alfonso Colombatti; Andrea Vecchione; Barbara Belletti; Gustavo Baldassarre
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

9.  Merkel cell polyomavirus small T antigen mediates microtubule destabilization to promote cell motility and migration.

Authors:  Laura M Knight; Gabriele Stakaityte; Jennifer J Wood; Hussein Abdul-Sada; David A Griffiths; Gareth J Howell; Rachel Wheat; G Eric Blair; Neil M Steven; Andrew Macdonald; David J Blackbourn; Adrian Whitehouse
Journal:  J Virol       Date:  2014-10-15       Impact factor: 5.103

10.  Stathmin Regulates Hypoxia-Inducible Factor-1α Expression through the Mammalian Target of Rapamycin Pathway in Ovarian Clear Cell Adenocarcinoma.

Authors:  Kazuhiro Tamura; Mikihiro Yoshie; Eri Miyajima; Mika Kano; Eiichi Tachikawa
Journal:  ISRN Pharmacol       Date:  2013-05-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.